Background:

Dipraglurant (ADX 48621) is a mGluR5 antagonists with IC50 of 0.021 μM. IC50 Value: 0.021 μM [1]Target: mGluRDipraglurant (ADX-48621) from Addex Therapeutics showed in vivo activity in different anxiety models in rat50 and is currently in phase II for the treatment of dyskinesia in Parkinson's disease.

参考文献:
[1]. The Synthesis and Use of Certain Pyridine Derivatives as Modulators of the G-protein Coupled Receptors mGlu5 and P2Y12